日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions

临床相关P-糖蛋白介导的药物相互作用的实用评估方案

Bogaard, Leonie; Tsoi, Kayan; van de Steeg, Bas; Brandon, Esther F A; Geers, Lisanne; van Herwaarden, Margreet; Jansman, Frank; Maas, Dominique; Monster-Simons, Margje; Ong, David S Y; Borgsteede, Sander D

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe

欧洲治疗2型糖尿病药物三期临床试验剂量论证审查

Koomen, Jeroen V; Stevens, Jasper; Monster-Simons, Margje H; Heerspink, Hiddo J L; Mol, Peter G M

Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment

对药品产品特性概要(SmPC)中有关肝功能不全患者用药信息的评估

Weersink, Rianne A; Timmermans, Lotte; Monster-Simons, Margje H; Mol, Peter G M; Metselaar, Herold J; Borgsteede, Sander D; Taxis, Katja

Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis

基于循证医学的建议,旨在提高肝硬化患者用药安全。

Weersink, Rianne A; Bouma, Margriet; Burger, David M; Drenth, Joost P H; Harkes-Idzinga, S Froukje; Hunfeld, Nicole G M; Metselaar, Herold J; Monster-Simons, Margje H; Taxis, Katja; Borgsteede, Sander D

Safe use of proton pump inhibitors in patients with cirrhosis

在肝硬化患者中安全使用质子泵抑制剂

Weersink, Rianne A; Bouma, Margriet; Burger, David M; Drenth, Joost P H; Harkes-Idzinga, S Froukje; Hunfeld, Nicole G M; Metselaar, Herold J; Monster-Simons, Margje H; van Putten, Sandra A W; Taxis, Katja; Borgsteede, Sander D

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion

通过文献回顾和专家意见评估药物在肝硬化患者中的安全性和剂量

Weersink, Rianne A; Bouma, Margriet; Burger, David M; Drenth, Joost P H; Hunfeld, Nicole G M; Kranenborg, Minke; Monster-Simons, Margje H; van Putten, Sandra A W; Metselaar, Herold J; Taxis, Katja; Borgsteede, Sander D